The 2026 pooled meta-analysis of tesamorelin trials is the cleanest data set we have on the only FDA-approved peptide on the Limitless menu. Across five randomized controlled studies, the headline numbers are a mean reduction of 27.7 cm² in visceral adipose tissue (VAT) and a mean increase of 1.42 kg in lean body mass, on a standard dose of 2 mg subcutaneously at bedtime. Both numbers are clinically meaningful, and the lean-mass preservation matters more than most readers will appreciate.
Why visceral fat is the right endpoint.
Subcutaneous fat — the fat you can pinch — is largely metabolically inert. Visceral fat is the deep, organ-encasing tissue that secretes inflammatory cytokines, drives insulin resistance, infiltrates the liver, and tracks with cardiovascular events. Two patients with the same BMI and waist measurement can have radically different VAT compartments, and the one with the larger VAT carries the larger long-term risk. Tesamorelin's selectivity for VAT is the key feature of the molecule.
The lean mass finding is the most underrated number.
GLP-1 agonists, the dominant weight-loss therapy of this era, reliably reduce lean mass alongside fat mass — somewhere between 25% and 40% of the weight lost is muscle, depending on the trial. That is a real cost. Tesamorelin's mechanism is the opposite: by stimulating endogenous growth hormone release in physiologic pulses, it pushes the body toward visceral lipolysis while protecting — and modestly building — skeletal muscle. The +1.42 kg lean-mass signal is the reason tesamorelin is increasingly being paired with GLP-1s rather than viewed as a competitor.
The cognitive endpoint is now in the picture.
The 2024–2026 trial series in adults with subjective cognitive impairment reports modest but consistent gains in executive function, working memory, and processing speed after 20–26 weeks of standard dosing. The effect sizes are smaller than the body-composition effect, and we do not promise cognitive benefit to patients selecting tesamorelin for visceral fat. We do disclose it as a credible secondary endpoint and track it informally — the molecule appears to be a rare "systemic optimizer" that moves metabolic and cognitive endpoints in the same direction.
What the data does not show.
Tesamorelin is not a cosmetic weight-loss tool. Subcutaneous fat largely stays put, and the scale may not move dramatically. It is not a substitute for diet, training, or sleep — it works best layered on top of a baseline. And the long-tail safety data above 26 weeks is still maturing, which is why the Limitless protocol runs in 26-week courses with a 4-week washout and reassessment, rather than indefinite daily dosing.
How we use it.
Patients who fit are typically men with central adiposity, mildly elevated triglycerides or ALT/AST, a stalled body-composition trajectory despite reasonable lifestyle, and a desire to optimize the GH axis without exogenous HGH. The protocol — dosing, monitoring, and contraindications — lives at /protocols/tesamorelin. The short version: 2 mg SC at bedtime, baseline IGF-1 / glucose / lipids, 12-week and 26-week reassessment, hold or titrate down if IGF-1 climbs above the upper third of age-adjusted reference.